AllSci News
Prolium brings T-cell engager format to systemic sclerosis
Prolium Bioscience has initiated a first-in-human Phase I trial of PRO-203, a subcutaneously administered CD20×CD3 bispecific T-cell engager, in patients...
Porosome Therapeutics opens India partnership to validate secretory dysfunction theory across six diseases
Boston-based Porosome Therapeutics, Inc. has entered a drug development partnership with India's Council of Scientific and Industrial Research (CSIR), the...
Harbour BioMed and BioMap launch AI-native pipeline company for complex biologics discovery
Harbour BioMed (HKEX: 02142) and AI life sciences company BioMap have jointly announced the formation of MegaStream TechBio, a newly created AI-native...
HMNC Brain Health secures USD 50 million to advance dual depression programs toward Phase III
Germany-based HMNC Brain Health (HMNC Holding GmbH) has closed a USD 50 million first closing of its Series B financing round, paired with a strategic...
Halia’s first-in-class NEK7 modulator secures FDA fast track for lower-risk MDS
Lehi, Utah-based Halia Therapeutics, Inc. announced receipt of US FDA Fast Track Designation for ofirnoflast (HT-6184), a first-in-class oral allosteric modulator of…
Inhibrx seeks first systemic therapy approval in chondrosarcoma with ozekibart filing
San Diego-based Inhibrx Biosciences, Inc. (Nasdaq: INBX) announced that the US FDA has accepted a Biologics License Application (BLA) for ozekibart (INBRX-109),…
Human Continuum raises USD 5m in seed funding for exosome-based longevity platform
Jupiter, Florida-based Human Continuum Inc. has closed a USD 5.13 million seed financing round to advance its exosome-based therapeutics and diagnostics...
Lilly's Jaypirca on course to reshape post-BTKi CLL treatment after beating venetoclax
Eli Lilly and Company (NYSE: LLY) reported Phase III data showing pirtobrutinib (Jaypirca) added to a time-limited venetoclax-based regimen cut the risk of...
Legend Bio's CD19/CD20 in vivo CAR-T demonstrates proof of concept in non-Hodgkin lymphoma
Early clinical data from Bridgewater, New Jersey-based Legend Biotech Corporation (Nasdaq: LEGN) suggest that LB2501, its investigational in vivo CD19/CD20...
Full Phase III data reinforce Intellia's lead in race to first In Vivo CRISPR approval
Full Phase III data for lonvoguran ziclumeran (lonvo-z) — published simultaneously in the New England Journal of Medicine and presented at the European...
J&J's Talvey plus Darzalex combo hits PFS endpoint in Phase III multiple myeloma trial
Phase III data from the MonumenTAL-3 trial, reported by Johnson & Johnson (NYSE: JNJ) at the 2026 European Hematology Association Annual Meeting,...
Tzield moves beyond disease delay as FDA approves post-diagnosis use in Type 1 diabetes
Sanofi’s Tzield (teplizumab-mzwv) has received US FDA accelerated approval for a new indication as the first disease-modifying therapy for children aged 8…
Merck’s Welireg and Keytruda combo gets FDA clearance as adjuvant for clear cell kidney cancer
The US FDA has approved Welireg (belzutifan) in combination with Keytruda (pembrolizumab) — and its subcutaneous equivalent Keytruda QLEX (pembrolizumab and berahyaluronidase…
Traws faces regulatory setbacks for tivoxavir marboxil in influenza challenge trial
A negative regulatory review from the UK's Medicines and Healthcare Products Regulatory Agency has effectively halted the most advanced clinical milestone...
AstraZeneca’s Truqap gets FDA nod for PTEN-deficient prostate cancer alongside Roche diagnostic
The US FDA approved AstraZeneca’s Truqap (capivasertib) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive…
The AllSci Brief
Free, systematic R&D and deal news. Daily.